![](https://investorshub.advfn.com/uicon/367184.png?cb=1553590500)
Tuesday, April 12, 2022 6:02:34 AM
Source: TipRanks
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Genocea Biosciences (GNCA – Research Report) yesterday. The company's shares closed last Monday at $0.60, close to its 52-week low of $0.39. According to TipRanks.com, Graybosch 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.6% and a 31.9% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Genocea Biosciences is a Strong Buy with an average price target of $5.68, implying an 890.8% upside from current levels. In a report issued on April 10, Robert W.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-genocea-biosciences-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM